Lucid Capital Markets analyst Dev Prasad initiates coverage on Faeth Therapeutics (NASDAQ: FTH) with a Buy rating and a price ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage